Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4952W HIGH $1.93
Volume
385.90 K
Value Traded
55.57 K
Short % Float
1.11%
Days to Cover
2.2
-8.56%Week
-36.93%1 Month
+16.83%3 Month
-25.63%6 Month
-91.68%5 Year
-91.68%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
70.55 M
EPS (TTM)
-0.44
P/E Ratio
-
Ent. Value
54.51 M
Total Shares
105.76 M
Float Shares
26.09 M
Insiders
71.95%
Institutions
15.21%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CTOR Catalyst Timeline
Dated clinical, regulatory and corporate events for Citius Oncology, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Citius Oncology, Inc.
115Total events
4Upcoming
30Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Product LaunchLYMPHIRApprovedPost-Market
LYMPHIR launch progresses with 44 institutions ordering
relapsed or refractory Stage I-III CTCLsource ↗
▲Enrollment MilestoneLYMPHIRApprovedTrial
LYMPHIR ordered by 44 institutions since launch
CTCLsource ↗
▲Equity OfferingCorporate
Received approximately $9.7 million in net proceeds from exercise of warrants
▲Debt Royalty FinancingCorporate
Funded $10.0 million under first tranche of senior secured term loan facility
▲Trial InitiationLYMPHIRApprovedTrial
Advancing investigator-initiated Phase 1 studies of LYMPHIR in combination regimens beyond CTCL
CTCLsource ↗
▲Quarterly UpdateLYMPHIRApprovedCorporate
Near-universal payer coverage secured
relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL)source ↗
●Oral PresentationLYMPHIRApprovedPresentation
Met with CTCL key opinion leaders at Sixth World Congress of Cutaneous Lymphomas in Montreal
cutaneous T-cell lymphoma (CTCL)source ↗
▲Quarterly UpdateCorporate
Expanded commercial organization to 29-person nationwide coverage in August 2026
▲Quarterly UpdateCorporate
July 2026 institutional vial orders were 383, largest month to date
▲Quarterly UpdateLYMPHIRApprovedCorporate
383 institutional vials ordered in July 2026, largest month to date
▲Quarterly UpdateLYMPHIRApprovedCorporate
Commercial launch update: expanded teams and market adoption
relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL)source ↗
▲Quarterly UpdateLYMPHIRApprovedCorporate
Anticipates more than 20 additional institutions during current quarter
relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL)source ↗
▲Quarterly UpdateLYMPHIRApprovedCorporate
Institutional vial orders grew 31% sequentially to 926 in Q3 FY2026
▲Equity OfferingCorporate
Received approximately $9.7 million in net proceeds from warrant exercises
▲Debt Royalty FinancingCorporate
Funded $10.0 million under first tranche of senior secured term loan facility
▲Oral PresentationLYMPHIRApprovedPresentation
Phase 1 data for LYMPHIR with pembrolizumab presented at ASCO 2026
recurrent or refractory gynecologic cancerssource ↗
●Manufacturing MilestoneLYMPHIRApprovedCMC / Inspection
Initiated evaluation of new bulk drug substance suppliers; letter of intent with new CMO expected by end of June 2026
▲Oral PresentationLYMPHIRApprovedPresentation
Phase 1 data for LYMPHIR with pembrolizumab presented at ASCO 2026
recurrent or refractory gynecologic cancerssource ↗
▲Poster PresentationLYMPHIRApprovedPresentation
Phase 1 data of LYMPHIR + pembrolizumab presented at ASCO 2026
recurrent or refractory gynecologic malignanciessource ↗
●AbstractLYMPHIRApprovedPresentation
Abstract for LYMPHIR + pembrolizumab Phase 1 study made available on ASCO website
relapsed/refractory gynecologic malignanciessource ↗
▲Topline ReadoutLYMPHIRApprovedClinical Data
Positive topline safety and efficacy results from Phase 1 trial prior to CAR-T in DLBCL
high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL)source ↗
▼Equity OfferingCorporate
Concurrent exercise of outstanding warrants for ~$11.5 million gross proceeds
▼Debt Royalty FinancingCorporate
Up to $25 million senior credit facility from Avenue Capital Group, initial $10 million tranche funded
▲Product LaunchLYMPHIRApprovedPost-Market
Initial shipment of LYMPHIR to Europe through regional distribution partner
relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL)source ↗
▲Other Regulator MilestoneLYMPHIRApprovedEx-US Regulatory
Initiated first European shipment via Named Patient Programs
CTCLsource ↗
◆Oral PresentationLYMPHIRApprovedPresentation
Citius Oncology to attend USCLC Annual Workshop 2026 to discuss LYMPHIR with CTCL experts
cutaneous T-cell lymphoma (CTCL)source ↗
▲Topline ReadoutLYMPHIRApprovedClinical Data
Positive topline results from Phase 1 study of LYMPHIR in combination with pembrolizumab in relapsed or refractory gynecologic cancers
relapsed or refractory gynecologic cancerssource ↗
▲Topline ReadoutLYMPHIRApprovedClinical Data
Preliminary topline Phase 1 data of LYMPHIR prior to CAR-T in DLBCL
high-risk relapsed or refractory diffuse large B-cell lymphomasource ↗
●Oral PresentationLYMPHIRApprovedPresentation
Full results presented at 2026 ASTCT & CIBMTR Tandem Meetings
high-risk relapsed or refractory diffuse large B-cell lymphomasource ↗
▲Topline ReadoutLYMPHIRApprovedClinical Data
Positive topline data from investigator-sponsored study of LYMPHIR prior to CAR-T therapy in DLBCL
relapsed/refractory diffuse large B-cell lymphomasource ↗
▲Oral PresentationLYMPHIRApprovedPresentation
Presentation of positive topline data at ASTCT 2026 Annual Meeting
relapsed/refractory diffuse large B-cell lymphomasource ↗
▲Partnership / LicenseLYMPHIRApprovedCorporate
Executed distribution agreements across Europe and the Middle East for international expansion
▲Partnership / LicenseLYMPHIRApprovedCorporate
Exclusive distribution agreement with Uniphar for LYMPHIR in Western and Eastern Europe
relapsed or refractory cutaneous T-cell lymphoma (CTCL)source ↗
▲Oral PresentationLYMPHIRApprovedPresentation
Phase 1 data for LYMPHIR prior to CAR-T presented at 2026 Tandem Meetings
high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL)source ↗
▲Oral PresentationLYMPHIRApprovedPresentation
Phase 1 data for LYMPHIR with pembrolizumab presented at ASCO 2026
recurrent or refractory gynecologic cancerssource ↗
◆Interim AnalysisLYMPHIRApprovedTrial
Preliminary results of LYMPHIR in combination with CAR T therapy
high risk relapsed/refractory B-cell lymphomassource ↗
◆Topline ReadoutLYMPHIRApprovedClinical Data
Phase 1 study data (n=25) anticipated
recurrent or metastatic solid tumorssource ↗
▼Equity OfferingCorporate
Closed $18 million concurrent registered direct offering and private placement
▼Equity OfferingCorporate
Announced $18 million concurrent registered direct offering and private placement
◆Oral PresentationLYMPHIRApprovedPresentation
Exhibit at 67th ASH Annual Meeting
relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL)source ↗
▲Partnership / LicenseLYMPHIRApprovedCorporate
Exclusive distribution agreement with Er-Kim for Turkey and GCC countries
cutaneous T-cell lymphomasource ↗
Past FDA Catalysts and PDUFA Decisions
How CTOR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every CTOR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| LYMPHIR | recurrent or refractory gynecologic malignancies | Phase 1 | 2026-06-01 | overall response rate: 24%; median progression free survival: 20.5 months; clinical benefit: 48% (10 of 21); objective response rate endometrial cancer: 33%; median duration of response: 21.1 months; overall median progression free survival: 5.8 monthsRead More | Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic MalignanciesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CTOR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CTOR for Q2 2026. | ||||
CTOR Institutional Ownership Trends
CTOR Short Interest
Shares sold short, counted twice a month.
1.11%
Short % of Float
of tradable shares sold short
289.7K
Shares Sold Short
-43.1% vs prior count
2.2 Moderate
Days to Cover
trading days of normal volume to buy every short share back
129.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CTOR ranks across every disease it competes in
Competitive Position is a premium feature
See how CTOR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCTOR News
CTOR▲ +14.9%today
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
Citius Oncology reported a 120% increase in LYMPHIR unit sales to U.S. wholesalers during the fiscal fourth quarter of 2026. The company aims to have LYMPHIR on formulary at 100 priority institutions by year-end. The demand for LYMPHIR is expected to continue growing as it becomes more established in treating cutaneous T-cell lymphoma.
Read more →CTOR▼ -18.7%on this news
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Citius Oncology, Inc. reported strong financial results for Q3 2026, with $7.1 million in revenue driven by increased institutional demand for its product, LYMPHIR. The company noted a 31% sequential growth in vial orders and expanded its commercial team to support broader market access. Despite a net loss of $8.9 million, the positive trajectory in demand and revenue gives management confidence for the remainder of the fiscal year.
Read more →CTOR▲ +11.2%on this newsshared move
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
Citius Oncology has appointed Jonathan Peri, Ph.D., J.D., as an independent director, expanding its Board to nine members. Dr. Peri brings extensive experience in governance and leadership across various sectors. His appointment is expected to enhance the company's strategic oversight as it focuses on the commercial launch of its oncology therapy, LYMPHIR.
Read more →CTOR▲ +18.9%on this news
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
Citius Oncology reported significant commercial progress for its cancer treatment LYMPHIR, with a 78% increase in new institutional accounts ordering the drug. The company highlighted its expanding formulary approvals and the growing number of institutions now utilizing LYMPHIR. The treatment, indicated for relapsed or refractory cutaneous T-cell lymphoma, is gaining traction in the market with strong payer coverage.
Read more →CTORCitius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
Citius Oncology has expanded its commercial and medical affairs teams to support the launch of LYMPHIR, a treatment for cutaneous T-cell lymphoma. The company anticipates full deployment of its expanded team by August 2026, following a recent financing round. With nearly complete payer coverage and positive physician feedback, Citius Oncology is optimistic about LYMPHIR's market adoption and growth in the latter half of 2026.
Read more →CTORCitius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Citius Oncology presented Phase 1 clinical data for LYMPHIR in combination with pembrolizumab at the ASCO Annual Meeting. The study showed an overall response rate of 24% and a median progression-free survival of 20.5 months among patients who achieved clinical benefit. The combination demonstrated promising results in heavily pre-treated patients with recurrent gynecologic malignancies, although LYMPHIR remains investigational for these indications. Further studies are planned to explore this treatment combination more extensively.
Read more →CTORCitius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
Citius Oncology announced that data from its Phase 1 combination study of LYMPHIR with pembrolizumab will be presented at the upcoming ASCO Annual Meeting. The study reported a 24% objective response rate with an average duration of response of 21.1 months among responders, alongside a favorable safety profile. The presentation reflects significant clinical interest in LYMPHIR in treating relapsed or refractory gynecologic malignancies. The study's results indicate potential benefits, although the findings are preliminary and investigational.
Read more →CTORCitius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Oncology, Inc. announced its fiscal second quarter 2026 financial results, reporting $5.6 million in net revenue driven by the launch of LYMPHIR. The company achieved broad payer coverage and significant formulary inclusion, with 83% of target accounts engaged. However, it also reported a net loss of $26.6 million, primarily due to increased administrative expenses. Citius secured up to $36.5 million in financing to support its commercial efforts.
Read more →CTORCitius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
Citius Oncology, Inc. has secured up to $36.5 million in debt and equity capital to accelerate the commercialization of LYMPHIR, an FDA-approved therapy for cutaneous T-cell lymphoma. The funding includes a $25 million senior credit facility and $11.5 million from warrant exercises. This financial support aims to enhance the company's commercial execution and expand patient access to LYMPHIR.
Read more →CTORCitius Oncology Ships First International Order of LYMPHIR™ to Europe
Citius Oncology has shipped its first international order of LYMPHIR to Europe, enhancing access for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). This shipment is facilitated through Named Patient Programs, allowing physicians to request the therapy under local regulations. The company is also seeing positive adoption rates in the U.S. market since its launch.
Read more →CTOR▲ +25.7%on this news· ran to +39% by day 3
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Oncology has reported encouraging early adoption of LYMPHIR for cutaneous T-cell lymphoma, with significant institutional uptake and broad payer coverage. The company noted a sequential growth in orders and no reimbursement denials, indicating strong market integration. Additionally, ongoing clinical studies are exploring LYMPHIR's potential in combination therapies, further supporting its role in oncology.
Read more →CTOR▼ -6.8%on this news· ran to -18% by day 3
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology will participate in the USCLC Annual Workshop 2026, focusing on cutaneous T-cell lymphoma (CTCL). The event will facilitate discussions between leading experts and Citius's team regarding the treatment landscape and clinical experiences with LYMPHIR, their recently launched therapy. The workshop aims to enhance collaboration and knowledge exchange in CTCL care.
Read more →CTORCitius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Citius Oncology announced positive topline results from a Phase 1 study evaluating LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers. The study showed no unexpected safety signals and a promising objective response rate of 24%. Full results will be presented at an upcoming cancer conference, highlighting the potential of this combination therapy.
Read more →CTORCitius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
Citius Oncology announced positive topline results from a Phase 1 trial of LYMPHIR (E7777) in patients with high-risk diffuse large B-cell lymphoma (DLBCL). The study showed an 86% overall response rate, with 57% achieving complete response. LYMPHIR was well-tolerated, and no dose-limiting toxicities were reported. The findings suggest that LYMPHIR may enhance the efficacy of CAR-T therapies.
Read more →CTORCitius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Citius Oncology reported $3.9 million in first-quarter revenue following the December launch of LYMPHIR. The company recorded a net loss of $5.5 million for the period ended December 31, 2025. Cash and cash equivalents stood at $7.3 million at quarter end. This marks the firm's transition to a commercial-stage oncology business.
Read more →CTORCitius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
Citius Oncology has signed an exclusive distribution agreement with Uniphar to expand access to its drug LYMPHIR in Europe. This marks the company's third international distribution partnership, aimed at improving treatment options for patients with relapsed or refractory cutaneous T-cell lymphoma. The agreement allows Uniphar to manage access and distribution in specific territories, although LYMPHIR is not yet commercially available outside the U.S.
Read more →CTOR▼ -9.8%on this news
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. reported strong financial results for FY 2025, highlighted by the U.S. launch of LYMPHIR, a targeted immunotherapy. The company secured $36 million in financing to support commercialization efforts. CEO Leonard Mazur emphasized the focus on driving adoption and expanding international access. The initial market for LYMPHIR is estimated to exceed $400 million.
Read more →CTORCitius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology has successfully closed an $18 million registered direct offering and private placement, selling shares at $1.09 each. The proceeds will be utilized for the commercial launch of LYMPHIR, an FDA-approved treatment for CTCL. The company aims to capitalize on a growing market that is currently underserved.
Read more →CTOR▲ +6.4%on this newsshared move
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules Proceeds strengthen cash position and support commercial launch of LYMPHIR , a nov
Citius Oncology has announced an $18 million fundraising effort through a registered direct offering and private placement to bolster its financial position. The funds are earmarked for the commercial launch of LYMPHIR, a new treatment for cutaneous T-cell lymphoma. The closing of the offerings is expected by December 10, 2025, pending customary conditions. LYMPHIR has gained FDA approval and addresses a significant market need for patients with relapsed or refractory CTCL.
Read more →About Citius Oncology, Inc.
Headquarters11 COMMERCE DRIVE, CRANFORD, NJ, 07016
BIOPHARMAWATCH ELITE PLUS
Trade the next CTOR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime